Neuralstem Announces Topline Results Of Phase II ALS Trial

GERMANTOWN, Md., March 12, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery

Final Patient Treated in Phase 2 ALS Stem Cell Trial

Drug Discovery & Development, Source: Neuralstem ~ August 4, 2014 Neuralstem Inc. announced that the final patient was treated in its Phase 2 trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The multicenter Phase 2 trial treated 15 ambulatory patients in five different

FDA-approved Stem Cell Trial Dramatically Slows ALS

Thu, 2013-05-30 13:34 - published in, by Cynthia Fox   University of Michigan neurologist Eva Feldman, president of the American Neurological Association and Principle Investigator on the neural stem cell ALS trial. For an unheard-of two years, stem cells have slowed the progression of Lou Gehrig’s disease, a devastating condition with a two-to-five year

FDA Approves Phase II Stem Cell Trial for Lou Gehrig’s Disease

Medical Daily ~ By Susan Scutti Designed to treat up to 15 patients in five different dosing cohorts, Neuralstem's Phase II trial will use NSI-566 spinal cord-derived human neural stem cells in the treatment of ALS. "The aim of this Phase II trial is to obtain the maximum tolerated dose using the same route of

Rockville biotech tests stem cells for depression

Monday, July 2, 2012 By: Gazette staff Neuralstem, the Rockville company that's developing a stem cell treatment for patients with amyotrophic lateral sclerosis, has begun testing the safety of its treatment for major depressive disorder. The compound, NSI-189, stimulates new neuron growth in the brain's hippocampus region, which scientists think is involved in depression and

Neuralstem Updates ALS Stem Cell Trial Progress

Tuesday, May 22, 2012 By: Neuralstem Press Release FDA permits additional dosing of return patients ROCKVILLE, Md., May 8, 2012 /PRNewswire via COMTEX/ -- Neuralstem, Inc. announced that the Federal Drug Administration (FDA) has approved the return of three patients from earlier cohorts in its ongoing Phase I safety trial to treat amyotrophic lateral sclerosis